| Autor: |
Gary Garber, RT Noel Gibney, Bruce Light, Claudio Martin, Kenneth Cunningham, Jean-Gilles Guimond, Sheldon Magder, James Russell |
| Jazyk: |
angličtina |
| Rok vydání: |
2002 |
| Předmět: |
|
| Zdroj: |
Canadian Journal of Infectious Diseases, Vol 13, Iss 6, Pp 361-372 (2002) |
| Druh dokumentu: |
article |
| ISSN: |
1180-2332 |
| DOI: |
10.1155/2002/916317 |
| Popis: |
Approximately one-third of cases of severe sepsis result in death. Endogenous activated protein C (ApC) plays a key role in the regulation of the inflammation, fibrinolysis and coagulation associated with severe sepsis. In a recently published phase III trial, protein C Worldwide Evaluation in Severe Sepsis (pROWESS), intravenous administration of recombinant human ApC (rhApC) 24 µg/kg/h for 96 h to patients with severe sepsis resulted in a 6.1% reduction in absolute mortality and a 19.4% reduction in the relative risk of death from any cause within 28 days (number needed to treat = 16). This dose is now being applied in clinical practice. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
